Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

BRAF or MEK1/2 inhibitors are cytostatic in melanoma and the surviving cells develop drug resistance. This study shows that the pro-survival pool is biased towards MCL1 in melanoma so that BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1 inhibitor AZD5991, improving tumour growth inhibit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthew J. Sale, Emma Minihane, Noel R. Monks, Rebecca Gilley, Frances M. Richards, Kevin P. Schifferli, Courtney L. Andersen, Emma J. Davies, Mario Aladren Vicente, Eiko Ozono, Aleksandra Markovets, Jonathan R. Dry, Lisa Drew, Vikki Flemington, Theresa Proia, Duncan I. Jodrell, Paul D. Smith, Simon J. Cook
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/03dfbb8e162440b8bfec0b14545e606c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:03dfbb8e162440b8bfec0b14545e606c
record_format	dspace
spelling	oai:doaj.org-article:03dfbb8e162440b8bfec0b14545e606c2021-12-02T15:35:49ZTargeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors10.1038/s41467-019-12409-w2041-1723https://doaj.org/article/03dfbb8e162440b8bfec0b14545e606c2019-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-12409-whttps://doaj.org/toc/2041-1723BRAF or MEK1/2 inhibitors are cytostatic in melanoma and the surviving cells develop drug resistance. This study shows that the pro-survival pool is biased towards MCL1 in melanoma so that BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1 inhibitor AZD5991, improving tumour growth inhibition.Matthew J. SaleEmma MinihaneNoel R. MonksRebecca GilleyFrances M. RichardsKevin P. SchifferliCourtney L. AndersenEmma J. DaviesMario Aladren VicenteEiko OzonoAleksandra MarkovetsJonathan R. DryLisa DrewVikki FlemingtonTheresa ProiaDuncan I. JodrellPaul D. SmithSimon J. CookNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-19 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Matthew J. Sale Emma Minihane Noel R. Monks Rebecca Gilley Frances M. Richards Kevin P. Schifferli Courtney L. Andersen Emma J. Davies Mario Aladren Vicente Eiko Ozono Aleksandra Markovets Jonathan R. Dry Lisa Drew Vikki Flemington Theresa Proia Duncan I. Jodrell Paul D. Smith Simon J. Cook Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
description	BRAF or MEK1/2 inhibitors are cytostatic in melanoma and the surviving cells develop drug resistance. This study shows that the pro-survival pool is biased towards MCL1 in melanoma so that BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1 inhibitor AZD5991, improving tumour growth inhibition.
format	article
author	Matthew J. Sale Emma Minihane Noel R. Monks Rebecca Gilley Frances M. Richards Kevin P. Schifferli Courtney L. Andersen Emma J. Davies Mario Aladren Vicente Eiko Ozono Aleksandra Markovets Jonathan R. Dry Lisa Drew Vikki Flemington Theresa Proia Duncan I. Jodrell Paul D. Smith Simon J. Cook
author_facet	Matthew J. Sale Emma Minihane Noel R. Monks Rebecca Gilley Frances M. Richards Kevin P. Schifferli Courtney L. Andersen Emma J. Davies Mario Aladren Vicente Eiko Ozono Aleksandra Markovets Jonathan R. Dry Lisa Drew Vikki Flemington Theresa Proia Duncan I. Jodrell Paul D. Smith Simon J. Cook
author_sort	Matthew J. Sale
title	Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
title_short	Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
title_full	Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
title_fullStr	Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
title_full_unstemmed	Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
title_sort	targeting melanoma’s mcl1 bias unleashes the apoptotic potential of braf and erk1/2 pathway inhibitors
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/03dfbb8e162440b8bfec0b14545e606c
work_keys_str_mv	AT matthewjsale targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT emmaminihane targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT noelrmonks targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT rebeccagilley targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT francesmrichards targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT kevinpschifferli targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT courtneylandersen targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT emmajdavies targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT marioaladrenvicente targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT eikoozono targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT aleksandramarkovets targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT jonathanrdry targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT lisadrew targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT vikkiflemington targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT theresaproia targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT duncanijodrell targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT pauldsmith targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors AT simonjcook targetingmelanomasmcl1biasunleashestheapoptoticpotentialofbrafanderk12pathwayinhibitors
_version_	1718386392870944768

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Ejemplares similares